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Objective: To evaluate the anti-diabetic potential of leaf extract from Urena lobata
(U. lobata) through dipeptidyl peptidase IV (DPP-IV) inhibitory activity.
Methods: U. lobata leaf was extracted in hot water and ethanol. The activity of DPP-IV
inhibitor was tested by in vitro study using gly-pro-p-nitroanilide as substrat of DPP-IV
and vildagliptin, as standard reference. A product of the reactions between gly-pro-p-
nitroanilide and DPP-IV, was observed by microplate readers with l = 405 nm. All
data were expressed as mean ± SD and the IC50 value was determined by non linear
regression curve ﬁt. Active substances in leaf extract of U. lobata was analyzed by liquid
chromatography-mass spectrometry. DPP-IV inhibitory activity of active compounds was
evaluated in silico using docking server.
Results: The ethanolic extract of U. lobata showed stronger DPP-IV inhibitor activity
than water extract with the IC50 values of 1 654.64 and 6 489.88 mg/mL, respectively.
Vildagliptin, based on standard reference for DPP-IV inhibitor activity, has IC50 value of
57.44 mg/mL. Based on in silico analysis, mangiferin, stigmasterol and b-sitosterol in
U. lobata extract have a strong inhibitory activity on DPP-IV.
Conclusions: The results showed that DPP-IV inhibitory activity of U. lobata is related
to its active compounds such as mangiferin, stigmasterol and b-sitosterol.1. Introduction
Recently, the treatment of type 2 diabetes mellitus is focused
on incretin hormone. Glucagon like peptide-1 (GLP-1) and
glucose dependent insulinotropic polypeptide (GIP) are the
major incretin hormones which are secreted by intestinal cells.
GLP-1 plays a role in regulation of blood glucose level due to
their biological actions, such as stimulating the secretion of in-
sulin, increasing b-cell mass, inhibiting the secretion of
glucagon, reducing the rate of gastric emptying and inducingsatiety [1,2]. However, GLP-1 is rapidly metabolized by the
enzyme called dipeptidyl peptidase IV (DPP-IV) into inactive
forms. Therefore, the GLP-1 has a short half life, approximately
for 1–2 min. Inhibition of DPP-IV maintains the level of
endogenous active GLP-1 and prolongs its half life [1,3].
DPP-IV inhibitor has the potential to be a novel, efﬁcient and
considerable agent to treat type 2 diabetes mellitus [3]. The usage
of DPP-IV inhibitor has less side effects like hypoglycemia,
increasing body weight and GIT disorders [4]. The studies of oral
glucose tolerance test on animals showed that genetic deletion of
DPP-IV have improved glucose tolerance and increased the in-
sulin secretion [5]. In the other hand, the complete data of long
term use of synthetic drugs of DPP-IV inhibitor have not been
obtained yet, especially on its safety [6]. It induces the research
of DPP-IV inhibitor compounds from herbs that are of less side
effects, cheaper and easier to get.open access article under the CC BY-NC-ND
Table 1
DPP-IV inhibitory activity of U. lobata leaf extracts and vildagliptin.








625.00 00.00 ± 0.00 6 489.88a
1 250.00 13.33 ± 0.00
2 500.00 26.67 ± 0.00
5 000.00 42.22 ± 3.85
10 000.00 62.22 ± 3.85
Ethanolic extract
of U. lobata
625.00 36.17 ± 0.00 1 654.64b
1 250.00 48.94 ± 0.00
2 500.00 55.32 ± 0.00
5 000.00 61.70 ± 0.00
10 000.00 74.47 ± 0.00
Vildagliptin 6.25 8.93 ± 0.00 57.44c
12.50 16.07 ± 4.12
25.00 37.50 ± 0.00
50.00 46.63 ± 3.85
100.00 60.71 ± 0.00
a, b, c: Different letters showed the differences of the potency (P < 0.05,
Least Signiﬁcant Difference test).
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Indonesia and has been used to cure many diseases. Based on
experiences, Nigerian people used U. lobata to treat diabetes
mellitus because of their biology activities [7]. The study showed
that administration of U. lobata roots extract had anti-
hyperglycemic effect on rat induced by streptozotocin before
[8]. It related to active substances in U. lobata such as sterol
groups, alkaloid and ﬂavonoid [9,10]. Anti-diabetic potential of
U. lobata has not been evaluated yet, especially the inhibition of
DPP-IV activity. Therefore it is an opportunity to expand herbs
that can become candidate of phytopharmaca. The aim of this
study was to know the anti-diabetic potential of U. lobata leaf
extract through inhibition of DPP-IV activity.
2. Materials and methods
2.1. Chemicals used
DPP-IV was obtained from porcine kidney. Gly-pro-p-
nitroanilide and Tris–HCl buffer were used. All chemicals
were purchased from Sigma Aldrich (St. Louis, MO, USA).
2.2. Sample preparation
U. lobata leaf powder was obtained from Materia Medika
Batu Malang with certiﬁcate number 074/027/101.8/2015. Then,
50 g of the powdered plant materials were extracted in 250 mL
hot water at 90 C for 30 min. Similarly, 50 g U. lobata powder
was extracted in 250 mL ethanol for 4 h by waterbath shaker and
repeated 2 times with fresh ethanol. Both of the extracts were
then evaporated.
2.3. Identiﬁcation of active compounds
Both water and ethanol extract were analyzed on a semi
qualitative scale by liquid chromatography–mass spectrometry
(LC–MS) Accela 1250 pump for identiﬁcation of active com-
pounds. Mobile phase contained 0.1% formic acid in a mixture
of methanol and water.
2.4. DPP-IV assays
The assay was performed in 96 micro well plates. A pre-
incubation solution (50 mL) contained 35 mL Tris–HCl buffer,
15 mL DPP-IV enzyme and various concentration (625, 1 250,
2 500, 5 000 and 10 000 mg/mL) of the extracts or standard
(6.25, 12.5, 25, 50 and 100 mg/mL). This mixture was incubated
at 37 C for 10 min, followed by addition of 50 mL gly-pro-p-
nitroanilide as substrate. The reaction mixture was incubated
for 30 min at 37 C and the absorbance was measured by
microplate readers at l = 405 nm every 10 s. Vildagliptin was
used as the standard DPP-IV inhibitor [11]. % Inhibition was
calculated by the following formula:
% Inhibition =
DPP− IV activity ðwith extractÞ
DPP− IV activity ðwithout extractÞ× 100
2.5. Molecular docking studies
DPP-IV inhibitory activity of active compounds in
U. lobata leaf extracts was evaluated by in silico study using aweb-based software application (www.dockingserver.com) for
protein and ligand molecular docking. Free energy binding,
inhibition constant and surface interactions were analyzed by
this method to measure the DPP-IV inhibitory activity of active
compounds.
2.6. Statistical analysis
All data are expressed as mean ± SD. The IC50 was deter-
mined by non-linear regression curve ﬁt. The statistical data
were analyzed by SPSS One-way ANOVA test followed by least
signiﬁcant difference test with signiﬁcant value at P < 0.05.
3. Results
3.1. DPP-IV inhibitory activity of U. lobata
Both water and ethanol U. lobata leaf extracts were tested on
DPP-IV inhibitory assay by in vitro method. The DPP-IV
inhibitory activity is shown in Table 1.
The results obtained in the DPP-IV inhibitory assay showed
that ethanolic extract of U. lobata showed stronger activity in
DPP-IV inhibition, about 4 times folds, compared to water
extract (P < 0.05). However, the DPP-IV inhibitory activity of
both water and ethanolic U. lobata extracts are still lower,
approximately 30–100 times folds, compared to vildagliptin as
reference drugs of DPP-IV inhibitor (P < 0.05).
3.2. Identiﬁcation of active compounds in U. lobata leaf
extracts
Ten active substances from alkaloid, ﬁtosterol and ﬂavonoid
groups were identiﬁed in extracts of U. lobata. The active
compounds, both in water and ethanol leaf extract of U. lobata,
can be seen in Table 2. The semi-qualitative analysis by LC–MS
showed that the most abundant active compounds both in water
and ethanolic extract of U. lobata were stigmasterol, gossypetin
and b-sitosterol. Active compounds such as mangiferin and
chrysoeriol were also identiﬁed in both water and ethanolic
extracts of U. lobata with less content.
Table 2
Active compounds in U. lobata leaf extracts.






Stigmasterol 413 +++ ++
b-Sitosterol 415 + +
Mangiferin 423 + +
Quercetine 303 − −
Kaempferol 286 − −
Hypolaetin 302 − −
Gossypetin 318 + ++
Luteolin 286 − −
Apigenin 270 − −
Chrysoeriol 300 + +
+: Weak; ++: Moderate; +++: Strong; −: Negative.
Table 3











Stigmasterol −7.42 3.62 962.48
b-Sitosterol −6.59 14.67 886.91
Mangiferin −7.66 2.43 742.75
Gossypetin −5.20 153.42 552.29
Chrysoeriol −4.66 386.05 539.84
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leaf extracts
Inhibitory activity of U. lobata leaf extracts on DPP-IV was
evaluated by in silico study. Active compounds identiﬁed in
U. lobata as ligand were docked with DPP-IV as protein target
and the results can be seen at Table 3.
Docking studies showed that mangiferin, stigmasterol and b-
sitosterol have a low value in both the binding free energy and
the inhibition constant but the surface interaction was high.
However, gossypetin and chrysoeriol have a higher value in
binding free energy and inhibition constant than other sub-
stances above. The differences in each parameter value caused
the distinction in inhibitory activity on DPP-IV.
4. Discussion
4.1. Identiﬁcation of active compounds in U. lobata leaf
extracts
Five active compounds were identiﬁed in U. lobata leaf
extract and had been found in both water and ethanol extract. It
is only different in the quantity or amount of active compounds
in both extracts. The active compounds are stigmasterol, gos-
sypetin, b-sitosterol, mangiferin and chrysoeriol. All of them are
classiﬁed into secondary metabolite groups and have biological
activity that can be used to cure diseases. Stigmasterol is one of a
group of plant sterols or phytosterols that are chemically similar
to animal cholesterol. Phytosterols are insoluble in water but
soluble in most organic solvents and contain one alcohol func-
tional group. Stigmasterol is an unsaturated plant sterol in the
plant fats or oils of soybean, calabar bean, rape seed, and in
various medicinal herbs. Studies about laboratory animals
treated by stigmasterol found that both cholesterol and sitosterolabsorption decreased 23% and 30%, respectively, over a 6-week
period. It also possesses potential antioxidant, hypoglycemic and
thyroid inhibiting properties [12,13].
Gossypetin is ﬂavonol or ﬂavone, a type of ﬂavonoid. It has
been isolated originally from the ﬂowers and the calyx of Hi-
biscus species. Gossypetin shows potential antioxidant, anti-
microbial, anti-mutagenic and anti-atherosclerotic activities
[14]. This compound is very soluble in chloroform and benzene,
and also moderately soluble in ethanol and ether, but insoluble
in water.
b-sitosterol is one of several phytosterols or plant sterols with
chemical structure similar to that of cholesterol. Sterols are
isoprenoid-derived molecules that have essential functions
typically in eukaryotes, and especially in higher plants. b-
sitosterol are white, waxy powder with characteristic odor. They
are hydrophobic and soluble in ethanol and chloroform but
insoluble in water [15]. It can be found in avocados, cucurbita
pepo, corn oil and soy beans; it also showed anti-cholesterol,
anti-inﬂamatory and immunomodulator effects [16].
Mangiferin is a xanthonoid, and a glucoside of norathyriol. It
was found in mangoes, Iris unguicularis and Anemarrhena
asphedelous. Mangiferin is soluble in hot diluted ethanol and
methanol but insoluble in water. Laboratory study has identiﬁed
a variety of pharmacology effect that associated with mangiferin
including anti-microbial, antioxidant activity, and anti-diabetic
effect in rodent [17,18].
Chrysoeriol is a ﬂavon, one of major ﬂavonoid classes. They
exhibit many activities such as anti-inﬂammation and anti-
histamine activities. It is soluble in alkalies solution and sufﬁ-
ciently soluble in water [19].
The presence of active compounds in extract was inﬂuenced
by polarity and extract solvent. Type of extract solvent impacts
the amount of active compounds in extract due to the difference
of their solubility in solvent. Secondly, polarity of active com-
pound also contributes to their solubility in solvent. Alkaloid,
terpenoid and steroid are soluble in non polar solvent like
acetone, diethyl ether and hexane. Meanwhile, ﬂavonoid, phenol
and glycoside dissolve in polar solvent such as water and
methanol [20,21]. It is appropriate with the determinate solubility
theory “like dissolve like” that polar substances will dissolve in
polar solvent and vice versa [20,22].
Generally, plants contain two major substances; they are
nutrition and non nutrition compounds. Primary metabolite or
nutrition compounds such as carbohydrate, protein, fatty acids
and phytosterol can be found in a huge proportion but they do
not have pharmacology effect. On the other hand, non nutrition
compounds or secondary metabolite like alkaloid, terpenoid,
ﬂavonoid and steroid are found in a small concentration but it
have pharmacology effect at certain dose [20]. Secondary
metabolites are derived from metabolism of primary
metabolite in plant but sometimes they have a toxic effect
especially if it is used in high dose. Most of ﬂavonoid and
terpenoid in herbs have a potency as antioxidant, antiseptic
and anti-inﬂammatory whereas steroid as anti-inﬂammatory
and sex hormone. But, the pharmacology effect of alkaloid is
difﬁcult to be predicted in medicinal plants because they have so
many biological activities [23].
Anti-diabetic effect of herbs is indicated by their potency to
decrease blood glucose level. The hypoglycemia effect is
controlled by active compounds like terpenoid, steroid, alkaloid
and ﬂavonoid but their mechanisms of work are different. Some
herbs work as anti-diabetes by mechanisms such as insulin
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dase inhibitor [24]. Anti-diabetic herbs have many active com-
pounds so that they have a possibility to work by multiple action
and result in interactions either synergistic or antagonistic.
Sometimes the interactions have both negative and positive
pharmacology effect [4].
4.2. Molecular docking of U. lobata leaf extracts
Molecular docking is nowwidely used to discover new ligands
for target of known structure. Potential compound can be screened
by free energy binding. The score of free energy binding repre-
sents binding afﬁnity of ligand to the target protein; the lower free
energy binding, the higher binding afﬁnity [25]. In addition,
inhibition constant can be predicted using bioinformatics
approach. The lowest inhibition constant indicates the most
potential compound. Other parameter is surface interaction. It
represents the molecular recognition between ligand and target
protein. The higher value of surface interaction, the higher
interaction possibilities of compounds interacting with the
target protein [26]. Based on the ﬁndings in the present study,
mangiferin have the lowest value of inhibition constants
followed by stigmasterol. It is related to binding free energy
and surface interaction of these compounds. In this study,
stigmasterol has the highest value of surface interaction
followed by b-sitosterol and mangiferin. A great result of
surface interaction showed a stronger binding between ligand
and protein target, so that the biology activity is higher. Based
on the in silico analysis, mangiferin has the lowest value in
binding free energy while stigmasterol and b-sitosterol were in
the second and third position. The lowest value of binding free
energy produces a strong binding molecule and then causes the
potential biology activity. Free energy binding and surface
interaction between ligand and protein target affects the
inhibitory activity of U. lobata leaf extract on DPP-IV.
Molecular docking studies are widely used to predict the
potential candidates of drugs in the pharmaceutical industry.
Binding orientation of these small molecules or active com-
pounds to their protein targets reveals their afﬁnity and activity
as possible candidates of drugs.
4.3. DPP-IV inhibitory activity of U. lobata
DPP-IV inhibitory activity of ethanolic extract of U. lobata is
stronger than that of water extract. It is regulated by the differ-
ences of both active compounds and their proportions in these
extracts. Semi qualitative test of U. lobata leaf extract by LC–
MS showed the contents of stigmasterol, b-sitosterol, gossypetin
and chrysoeriol which are higher than that of mangiferin,
quercetine and hypolaetin. Active compounds such as stigmas-
terol, b-sitosterol and gossypetin are soluble in semi-polar sol-
vents like alcohol but mangiferin and hypolaetin are insoluble.
The differences of solubility of active compounds in the solvents
will affect the percentages of active compounds in the extracts.
Both ethanolic and water extracts of U. lobata contain the
same active compounds but different in amounts. Content of
gossypetin is lower in water extract meanwhile content of stig-
masterol is higher in water extract than that in ethanolic extract,
but the proportions of chrysoeriol, mangiferin and b-sitosterol
are similar in both water and ethanolic extract. Non-polar com-
pounds such as stigmasterol, b-sitosterol and gossypetin could beextracted in water solvent even though in small amount. When
the water is boiled, their polarity will decrease so that it could be
extracted from semi-polar until non-polar compounds [27].
Molecular docking study of U. lobata leaf extract showed
inhibitory activity on DPP-IV. Three active compounds such as
mangiferin, stigmasterol and b-sitosterol showed a low value in
binding free energy. It means that the binding between ligand
and molecule target is easy so that cause a strong DPP-IV
inhibitory activity. It is also supported by a low value from in-
hibitions constant of mangiferin, stigmasterol and b-sitosterol
which showed a high DPP-IV inhibitory activity. The lower
value of inhibitions constant means that these compounds with
low doses are able to inhibit the DPP-IV activity. Surface
interaction between DPP-IV and three compounds above
showed a high score (stigmasterol: 962.48, b-sitosterol: 886.91,
and mangiferin: 742.75). The compound with higher value of
surface interaction has the potential to binding ligand and
molecule target, predicting a stronger biological activity.
DPP-IV or CD26 is a membrane-associated peptidase of 766
amino acids that is widely distributed in numerous tissues. DPP-
IV is hydrolase enzyme and also exists with a soluble circu-
lating form in plasma, and signiﬁcant DPP-IV-like activity is
detectable in plasma from humans and rodents. DPP-IV (CD26)
exerts its biological effects via two distinct mechanisms of action.
First, as a membrane-spanning protein, it binds adenosine
deaminase and when activated, conveys intracellular signals in-
dependent of its enzymatic function via dimerization and activa-
tion of intracellular signaling pathways. The signaling properties
of membrane-associated CD26 have been most extensively
characterized in T cells [27]. The second principal biological
activity of CD26 (DPP-IV) is its enzymatic function. The
enzymatic activity of CD26 is exhibited by the membrane-
spanning form of the molecule, and by the slightly smaller
circulating soluble form [27,28].
The substrates of CD26/DPP-IV are not speciﬁc to a partic-
ular peptides. The substrates of CD26/DPP-IV are proline or
alanine containing peptides and include growth factors, che-
mokines, neuropeptides and vasoactive peptides. DPP-IV prefers
substrates with an amino-terminal proline or alanine at position
2, but may also cleave substrates with non-preferred amino acids
at position 2. The structure of incretin hormone such as GLP-1
and GIP reveals a highly conserved alanine at position 2,
rendering these peptides ideal putative substrates for the
aminopeptidase DPP-IV [29].
A number of study showed that the importance of DPP-IV
mediated inactivation of GLP-1 as a key determinant of GLP-
1 and GIP bioactivity [30]. DPP-IV inhibition prevents the
degradation of active GLP-1 but does not increase the levels of
circulating total GLP-1 and does not prevent the kidney from
rapidly clearing GLP-1. DPP-IV inhibition also acutely de-
creases L cell secretion of GLP-1, likely via negative feedback
on the L cell. The biological activities of GLP-1 are stimulating
the secretion of insulin, increasing b-cell masses, inhibiting the
secretion of glucagon, reducing the rate of gastric-emptying and
inducing satiety that contribute to maintain blood glucose level
in type 2 diabetes mellitus [1,2].
Using of DPP-IV inhibitors, primarily for the treatment of
diabetes, relates to the potential effects of these inhibition on
immune function. DPP-IV/CD26 is expressed on T cells, plays a
functional role in T cell activation, and activates CD26 as
signaling cascade in the T cell. CD26 associates with CD45, and
Yudi Purnomo et al./Asian Pac J Trop Biomed 2015; 5(8): 645–649 649modulation of CD26 activity is frequently associated with
enhanced T cell proliferation in immune system [29]. CD26/
DPP-IV plays an important role in tumor biology, and is use-
ful as a marker for various cancers, with its levels either on the
cell surface or in the serum increased in some neoplasms and
decreased in others [31].
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